Evidence map›Paper›PMID 34114732›Full record

ArticleCancer reports (Hoboken, N.J.)2021

Bladder and upper urinary tract cancers as first and second primary cancers.

Guoqiao Zheng, Kristina Sundquist, Jan Sundquist, Asta Försti, Otto Hemminki, Kari Hemminki

Open access · goldAbstract read
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 7 countries.

Guoqiao ZhengDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-4337-9017
Kristina SundquistCenter for Primary Health Care Research, Lund University, Malmö, Sweden.
Jan SundquistCenter for Primary Health Care Research, Lund University, Malmö, Sweden.
Asta FörstiDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Otto HemminkiDepartment of Surgery, University Health Network, Toronto, Ontario, Canada.
Kari HemminkiDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Research Center · DEShimane University · JPUniversity Health Network · CA

Funding

Biomedicum Helsinki-säätiöChina Scholarship Council 201606100057European Union's Horizon 2020 research and innovation program, grant No 856620 (Chaperon)Finska läkaresällskapet grantsThe Swedish Research Council
6 · The paper itself

Abstract

backgroundPrevious population-based studies on second primary cancers (SPCs) in urothelial cancers have focused on known risk factors in bladder cancer patients without data on other urothelial sites of the renal pelvis or ureter.

aimsTo estimate sex-specific risks for any SPCs after urothelial cancers, and in reverse order, for urothelial cancers as SPCs after any cancer. Such two-way analysis may help interpret the results.

methodsWe employed standardized incidence ratios (SIRs) to estimate bidirectional relative risks of subsequent cancer associated with urothelial cancers. Patient data were obtained from the Swedish Cancer Registry from years 1990 through 2015.

resultsWe identified 46 234 urinary bladder cancers (75% male), 940 ureteral cancers (60% male), and 2410 renal pelvic cancers (57% male). After male bladder cancer, SIRs significantly increased for 9 SPCs, most for ureteral (SIR 41.9) and renal pelvic (17.2) cancers. In the reversed order (bladder cancer as SPC), 10 individual FPCs were associated with an increased risk; highest associations were noted after renal pelvic (21.0) and ureteral (20.9) cancers. After female bladder cancer, SIRs of four SPCs were significantly increased, most for ureteral (87.8) and pelvic (35.7) cancers. Female bladder, ureteral, and pelvic cancers associated are with endometrial cancer.

conclusionsThe risks of recurrent urothelial cancers were very high, and, at most sites, female risks were twice over the male risks. Risks persisted often to follow-up periods of >5 years, motivating an extended patient follow-up. Lynch syndrome-related cancers were associated with particularly female urothelial cancers, calling for clinical vigilance.

Indexed as

AgedAged, 80 and overFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrognosisRegistriesSwedenUreteral NeoplasmsUrinary Bladder Neoplasmscancer etiologyrelative riskrenal pelvic cancersecond primary cancerureter cancerurothelial cancer

Identifiers

PMID34114732
PMCPMC8714543
OpenAlexW3167868994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.